ABUS - Arbutus Biopharma Corp - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ABUS is currently covered by 2 analysts with an average price target of $6.21. This is a potential upside of $1.95 (45.77%) from yesterday's end of day stock price of $4.26.

Arbutus Biopharma Corp's activity chart (see below) currently has 97 price targets and 79 ratings on display. The stock rating distribution of ABUS is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 49.44% with an average time for these price targets to be met of 76.25 days.

Highest price target for ABUS is $5, Lowest price target is $5, average price target is $5.

Most recent stock forecast was given by KEAY NAKAE from CHARDAN CAPITAL on 14-Nov-2025. First documented stock forecast 03-Jul-2014.

Currently out of the existing stock ratings of ABUS, 4 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 15-Sep-2020

$5

$0.74 (17.37%)

$5

4 months ago
(14-Nov-2025)

4/14 (28.57%)

$0.48 (10.62%)

136

Buy Since 28-Jun-2022

$5

11 months 11 days ago
(31-Mar-2025)

2/6 (33.33%)

$1.26 (33.69%)

256

Buy Since 08-Dec-2021

$5

$0.74 (17.37%)

$5

1 years 1 months 21 days ago
(21-Jan-2025)

0/17 (0%)

$1.79 (55.76%)

Buy Since 02-Feb-2022

$5

$0.74 (17.37%)

4 years 1 months 12 days ago
(02-Feb-2022)

0/1 (0%)

$2.11 (73.01%)

Buy Since 27-Jul-2020

$7

4 years 8 months 14 days ago
(28-Jun-2021)

0/4 (0%)

$3.7 (112.12%)

Show more analysts

Please expand the browser size to see the chart

What is ABUS (Arbutus Biopharma Corp) average time for price targets to be met?

On average it took 76.25 days on average for the stock forecasts to be realized with a an average price target met ratio 49.44

Which analyst has the current highest performing score on ABUS (Arbutus Biopharma Corp) with a proven track record?

MICHAEL YEE

Which analyst has the most public recommendations on ABUS (Arbutus Biopharma Corp)?

Michael Yee works at UBS and has 14 price targets and 10 ratings on ABUS

Which analyst is the currently most bullish on ABUS (Arbutus Biopharma Corp)?

Jason Kolbert with highest potential upside - $9.74

Which analyst is the currently most reserved on ABUS (Arbutus Biopharma Corp)?

Madhu Kumar with lowest potential downside - -$0.26

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?